| Literature DB >> 23285051 |
Judith E Mueller1, Seydou Yaro, Macaire S Ouédraogo, Natalia Levina, Berthe-Marie Njanpop-Lafourcade, Haoua Tall, Régina S Idohou, Oumarou Sanou, Sita S Kroman, Aly Drabo, Boubacar Nacro, Athanase Millogo, Mark van der Linden, Bradford D Gessner.
Abstract
BACKGROUND: The development of optimal vaccination strategies for pneumococcal conjugate vaccines requires serotype-specific data on disease incidence and carriage prevalence. This information is lacking for the African meningitis belt.Entities:
Mesh:
Year: 2012 PMID: 23285051 PMCID: PMC3527509 DOI: 10.1371/journal.pone.0052464
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Age-specific annual incidence rates of pneumococcal meningitis, by group of serotype, Bobo-Dioulasso, Burkina Faso, March 2007–February 2009.
| 0–5 mo(N = 34,782) | 6–11 mo(N = 27,826) | 1–4 yrs(N = 201,240) | 5–9 yrs(N = 225,836) | 10–14 yrs(N = 225,836) | 15–19 yrs(N = 89,211) | 20–29 yrs(N = 178,422) | 30–39 yrs(N = 129,630) | ≥40 yrs(N = 388,890) | Total(N = 1,501,672) | |
| Any pneumococcal | 57.5 (35.1–88.8) | 43.1 (22.3–75.3) | 5.0 (2.4–9.1) | 10.6 (6.8–15.8) | 8.9 (5.4–13.7) | 14.6 (7.8–24.9) | 5.6 (2.7–10.3) | 6.2 (2.7–12.2) | 4.4 (2.6–7.0) | 8.9 (7.5–10.6) [134] |
| Any serotype (if serotyped) | 54.6 (32.9–85.3) | 39.5 (19.7–70.7) | 3.5 (1.4–7.2) | 7.1 (4.1–11.5) | 7.1 (4.1–11.5) | 14.6 (7.8–24.9) | 3.9 (1.6–8.1) | 3.1 (0.8–7.9) | 4.1 (2.4–6.7) | 7.3 (6.0–8.8) [109] |
| Serotype 1 | 5.8 (0.7–20.8) | 3.6 (0.09–20.0) | 1.0 (0.1–3.6) | 6.2 (3.4–10.4) | 5.8 (3.1–9.8) | 7.9 (3.2–16.2) | 3.4 (1.2–7.3) | 2.3 (0.5–6.8) | 2.1 (0.9–4.1) | 3.7 (2.8–4.8) [56] |
| 10-valent vaccine types | 14.4 (4.7–33.6) | 25.2 (10.0–51.8) | 2.0 (0.5–5.1) | 6.2 (3.4–10.4) | 5.8 (3.1–9.8) | 9.0 (3.9–17.7) | 3.9 (1.6–8.1) | 3.1 (0.8–7.9) | 2.3 (1.1–4.4) | 4.7 (3.7–6.0) [71] |
| 13-valent vaccine types | 14.4 (4.7–33.6) | 25.2 (10.0–51.8) | 2.5 (0.8–5.8) | 6.2 (3.4–10.4) | 5.8 (3.1–9.8) | 9.0 (3.9–17.7) | 3.9 (1.6–8.1) | 3.1 (0.8–7.9) | 2.6 (1.2–4.7) | 4.9 (3.8–6.1) [73] |
| Theoretical serotype coverage with 10- (13-) valent vaccine (%) | 26 (26) | 64 (64) | 57 (71) | 87 (87) | 82 (82) | 62 (62) | 100 (100) | 100 (100) | 56 (63) | 65 (67) |
Serotyping based on PCR on CSF [8] or Quellung reaction on isolates (if strain isolated and stored).
Rates are expressed per 100,000 inhabitants (95% confidence interval) [number of cases].
includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
Figure 1Monthly incidence rates of bacterial meningitis in Bobo-Dioulasso, Burkina Faso, March 2007 to December 2009.
a) Pneumococcal (black line) and meningococcal (grey line) meningitis. b) Age-specific rates of pneumococcal meningitis, by season. Black lines, dry season. Grey lines, rainy season. Full lines, all pneumococcal cases. Dashed lines, serotype 1 cases only. Asterixes, 95% confidence intervals of incidence rates of all pneumococcal cases do not overlap between dry vs. rainy season, suggesting statistical significance of difference.
Figure 2Serotype or -group distribution among carriage (dark gray) and pneumococcal cases (light gray), Burkina Faso, 2007–9.
Serotyping based on cerebrospinal fluid polymerase chain reaction testing [8] or Quellung reaction on invasive isolates; and on Quellung reaction for carriage isolates. Each panel A–C shows only serotypes that were found in this age category. A: children <1 years of age, 92 nasopharyngeal carriage and 32 cases. B: children 1–4 years of age, 98 carriage isolates (90 nasopharyngeal, 8 oropharyngeal) and 10 cases. C: children ≥5 years of age and adults, 203 carriage isolates (157 nasopharyngeal, 46 oropharyngeal) and 84 cases. NT, invasive isolates with serotypes not included in the PCR serotyping algorithm (29 primers); or carriage isolates yielding negative results in the Quellung reaction panel.
Age-specific prevalence of pneumococcal carriage, by serotype group, Bobo-Dioulasso, Burkina Faso, February 2008.
| Age groups (N) | ||||||||||
| 0–5 mo(N = 32) | 6–11 mo (N = 30) | 1–4 yrs (N = 66) | 5–9 yrs (N = 65) | 10–14 yrs (N = 65) | 15–19 yrs (N = 66) | 20–24 yrs(N = 64) | 25–29 yrs(N = 65) | 30–39 yrs (N = 66) | Total (N = 519) | |
| Documented nasopharyngeal carriage prevalence | ||||||||||
| Any pneumococci (%) | 66 (48–83) | 73 (57–90) | 58 (45–70) | 35 (23–47) | 31 (19–42) | 21 (11–31) | 14 (5–23) | 11 (3–19) | 18 (8–28) | 32 (28–36) |
| 10-valent vaccine types | 22 (7–37) | 27 (10–43) | 21 (11–31) | 11 (3–19) | 8 (1–14) | 5 (0–10) | 3 (0–8) | 3 (0–7) | 6 (0–12) | 10 (8–13) |
| 13-valent vaccine types | 31 (14–48) | 47 (28–66) | 32 (20–43) | 14 (5–22) | 9 (2–16) | 8 (1–14) | 3 (0–8) | 3 (0–7) | 8 (1–14) | 14 (11–18) |
| Non 13-valent vaccine types | 34 (17–52) | 33 (15–51) | 29 (18–40) | 23 (13–34) | 22 (11–32) | 15 (6–24) | 11 (3–19) | 9 (2–16) | 11 (3–18) | 19 (16–23) |
| Estimated overall nasopharyngeal plus oropharyngeal carriage prevalence | ||||||||||
| Extrapolation factor | 1.3 | 1.3 | 1.3 | 1.4 | 1.4 | 2.0 | 2.0 | 2.1 | 2.1 | 1.6 |
| Any pneumococci (%) | 84 (67–95) | 97 (83–100) | 77 (65–87) | 51 (38–63) | 45 (32–57) | 42 (30–55) | 28 (18–41) | 23 (14–35) | 39 (28–52) | 49 (45–53) |
Nasopharyngeal swabs were taken from all 519 participants and additional oropharyngeal swabs were taken from a subset of 145 participants aged 1 to 39 years. Serotyping based on Quellung reaction.
Prevalence percent (95% confidence interval).
includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F.
includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F.
An extrapolation factor was calculated for each age group as the ratio of pneumococcal carriage at any site to pneumococcal carriage in the nasopharynx.
Children <12 months had only naso-pharyngeal swabs, thus no specific extrapolation factor could be calculated. We assumed the factor to be similar as in 1- to 4-year-old children.
Figure 3Age-specific pneumococcal carriage prevalence by carriage site in pharynx among 145 participants with both naso- and oropharyngeal swabs.
Bobo-Dioulasso, 2008.
Propensity of pneumococcal serotypes for invasive disease (meningitis) given carriage, relative to other serotypes or -groups.
| Serotypeor -group | N Cases due to this Serotype | N Cases due toOther Serotypes | N Carriers ofthis Serotype | N Carriers ofOther Serotypes | Invasiveness Index as Odds Ratio (95% Confidence Interval) |
| 1 | 57 | 56 | 2 | 164 | 83.5 (20.6, 716.6) |
| 2 | 1 | 112 | 0 | 166 | ∞ |
| 3 | 1 | 112 | 4 | 162 | 0.3 (0.01, 3.7) |
| 4 | 0 | 113 | 2 | 164 | 0 (0, 2.8) |
| 5 | 3 | 110 | 0 | 166 | ∞ (1.2, ∞) |
| 6 | 4 | 109 | 20 | 146 | 0.3 (0.1, 0.8) |
| 7C | 0 | 113 | 10 | 156 | 0 (0, 0.5) |
| 9V | 0 | 113 | 3 | 163 | 0 (0, 1.9) |
| 12A/B/F | 9 | 104 | 3 | 163 | 4.7 (1.1, 27.5) |
| 13 | 0 | 113 | 3 | 163 | 0 (0, 1.9) |
| 14 | 6 | 107 | 10 | 156 | 0.9 (0.3, 2.8) |
| 15A | 0 | 113 | 4 | 162 | 0 (0, 1. 4) |
| 15B/C | 1 | 112 | 6 | 160 | 0.2 (0.01, 2.0) |
| 16F | 0 | 113 | 6 | 160 | 0 (0, 0.9) |
| 17F | 0 | 113 | 6 | 160 | 0 (0, 0.9) |
| 18 | 4 | 109 | 8 | 158 | 0.7 (0.2, 2.8) |
| 19A | 0 | 113 | 9 | 157 | 0 (0, 0.6) |
| 19B | 0 | 113 | 5 | 161 | 0 (0, 1.1) |
| 19F | 1 | 112 | 11 | 155 | 0.1 (0.0, 0.9) |
| 22F | 0 | 113 | 3 | 163 | 0 (0, 1.9) |
| 23F | 1 | 112 | 18 | 148 | 0.07 (0.0, 0.5) |
| 34 | 0 | 113 | 5 | 161 | 0 (0, 1.1) |
| 35B | 0 | 113 | 2 | 164 | 0 (0, 2.8) |
| 35F | 0 | 113 | 5 | 161 | 0 (0, 1.1) |
| 38/25F | 3 | 110 | 3 | 163 | 1.5 (0.2, 11.3) |
| 48 | 1 | 112 | 0 | 166 | ∞ |
| NT | 19 | 94 | 12 | 154 | 2.6 (1.1, 6.1) |
The invasiveness index was calculated using all cases of pneumococcal meningitis with serotype or -group information identified during the dry season months of 2007–2009 (N = 113) and pneumococcal carriage (N = 166) identified in Bobo-Dioulasso, Burkina Faso, March 2007– February 2009. Serotyping was based on cerebrospinal fluid polymerase chain reaction testing [8] or Quellung reaction on invasive isolates; and on Quellung reaction for carriage isolates. The table reports serotypes that were found in at least one meningitis case, found in at least three carriers, or included in 10- or 13-valent pneumococcal conjugate vaccines.
Discrimination within the serogroup or between serotypes not possible for some meningitis cases due to PCR algorithm.
PCR serotyping on invasive isolates or CSF cannot discriminate between 12A/B/F, while Quellung typing of carriage isolates identified 12F only.
Cornfield estimation of the confidence interval possible only under certain conditions.